Rising Biosciences (Rising Biosciences) Total Long-Term Assets : $0.00 Mil (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Rising Biosciences's Total Long-Term Assets for the quarter that ended in . 20 was $0.00 Mil.

Rising Biosciences Total Long-Term Assets Historical Data

The historical data trend for Rising Biosciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Total Long-Term Assets Chart

Rising Biosciences Annual Data

Trend

Total Long-Term Assets

Rising Biosciences Quarterly Data

Total Long-Term Assets

Rising Biosciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Rising Biosciences Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Total Long-Term Assets

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.